Drug Trial Radar · NCT03660059
A Study to Assess Safety and Efficacy of ASP015K in Participants With Rheumatoid Arthritis (RA) Who Had an Inadequate Response or Intolerance to Methotrexate (MTX)
Last checked: Nov 20, 2026Latest source record: Oct 21, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
385
Actual
Start
Sep 27, 2018
Primary completion
Apr 1, 2021
Study completion Nov 2, 2021
Sponsor
- Lead sponsor
- Astellas Pharma China, Inc.Astellas (ALPMY)
- Sponsor type
- Industry
- First posted
- Sep 6, 2018
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to verify the superiority of ASP015K in combination with MTX or with other disease-modifying antirheumatic drugs (DMARDs) over placebo in terms of efficacy in participants with rheumatoid arthritis (RA) who had an inadequate response or intolerance to MTX, as measured by the American College of Rheumatology (ACR) 20 response rate at Week 24. This study will also evaluate the pharmacokinetics and safety of ASP015K as well as efficacy and safety of long-term treatment with ASP015K (52 weeks).
Conditions
- Rheumatoid Arthritis (RA)
Interventions
PeficitinibDrug
Oral
PlaeboDrug
Oral
Disease-modifying antirheumatic drugs (DMARDs)Drug
As necessary concomitant medications, DMARDs listed below will be administered orally unless specified. For subjects who are inadequate responders to methotrexate (MTX): MTX. For subjects who are intolerant of MTX: either of DMARDs listed; hydroxychloroquine, salazosulfapyridine, gold (injection or oral), D-penicillamine, lobenzarit, actarit, bucillamine and iguratimod.
Primary outcomes
What the sponsor says the trial is designed to measure.
- American College of Rheumatology (ACR)20 response rate at Week 24Time frame: At Week 24
Locations
43 sites in 3 countries. Site status is shown where the registry gives one.
Site CN00048
Anhui, China
Site CN00045
Beijing, China
Site CN00054
Beijing, China
Site CN00050
Bengbu, China
Site CN00061
Changchun, China
Site CN00032
Changsha, China
Site CN00076
Chenzhou, China
Site CN00071
Guangdong, China
Site CN00016
Guangzhou, China
Site CN00052
Guangzhou, China
Site CN00063
Guangzhou, China
Site CN00072
Guangzhou, China
Site CN00058
Inner Mongolia, China
Site CN00074
Jieyang, China
Site CN00028
Jilin City, China
Site CN00069
Jining, China
Site CN00064
Jiujiang, China
Site CN00046
Kunming, China
Site CN00060
Nanjing, China
Site CN00070
Nanjing, China
Site CN00068
Ningbo, China
Site CN00075
Pingxiang, China
Site CN00066
Qingdao, China
Site CN00056
Shanghai, China
Site CN00047
Shantou, China
Site CN00053
Sichuan, China
Site CN00057
Tianjin, China
Site CN00062
Tianjin, China
Site CN00059
Wuhan, China
Site CN00067
Xining, China
Site CN00065
Xuzhou, China
Site CN00073
Zhengzhou, China
Site CN00049
Zhuzhou, China
Site KR00037
Gwangju, South Korea
Site KR00036
Incheon, South Korea
Site KR00033
Seoul, South Korea
Site KR00034
Seoul, South Korea
Site KR00035
Seoul, South Korea
Site TW00022
Taichung, Taiwan
Site TW00023
Taichung, Taiwan
Showing 40 of 43 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.